6-Chloro-4-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]-1,3,5-triazin-2(1H)-one → HCID 178517890, 화합물
반응식
Cl[C:2]1[NH:7][C:6](=[O:8])[N:5]=[C:4]([N:9]2[CH2:14][CH2:13][C:12]([C:16]3[CH:21]=[CH:20][C:19]([F:22])=[CH:18][CH:17]=3)([OH:15])[CH2:11][CH2:10]2)[N:3]=1>[OH-].[Pd+2].[OH-]>[F:22][C:19]1[CH:20]=[CH:21][C:16]([C:12]2([OH:15])[CH2:13][CH2:14][N:9]([C:4]3[N:3]=[CH:2][NH:7][C:6](=[O:8])[N:5]=3)[CH2:10][CH2:11]2)=[CH:17][CH:18]=1참가 물질
3
실험 절차
6-Chloro-4-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]-1,3,5-triazin-2(1H)-one (239 mg, 0.74 mmol) synthesized in Reference Synthesis Example 13 and palladium hydroxide-activated carbon catalyst (24 mg) were used to obtain the title compound (264 mg, quantitative) by synthesis in a similar manner to Reference Synthesis Example 3.
출처 및 근거
- ORD 기록
- ord-82ceee9d3fdb4d46965187001dd64c8a
- 출처 데이터셋
- uspto-grants-2016_08